Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 April 2025 | Story Precious Shamase | Photo Supplied
Sifiso Banda
Sifiso Banda balances library duties and academic goals, showcasing innovation and resilience at the UFS Qwaqwa Campus.

In the heart of the University of the Free State Qwaqwa Campus, Sifiso Banda's story is one of ambition, and the seamless fusion of seemingly disparate worlds. Balancing his role as Senior Assistant Officer: Circulations and TK Mopeli Makerspace in the library with the rigorous demands of a BSc Honours Degree in Computer Science, Banda has not only excelled but also inspired.

 

Overcoming challenges fuelled by dreams

"Computer Science is my primary passion," Banda explains, his voice resonating with determination. "Being in academia allows me to interact with ever-evolving technologies. I love problem-solving and creating new ideas to help my community. “However, the path was far from easy. Juggling a demanding job with intense academic pressure led to sleepless nights and near-burnout. "It required immense professionalism in time planning and management," he confesses. "I almost gave up, but the unwavering support of my colleagues and supervisors kept me going."

Banda's journey is a testament to the power of perseverance, fuelled by a deep sense of responsibility and gratitude. "I had to remind myself daily who I was doing this for," he says, his voice filled with emotion. "My late mother used her last savings to register me for university, giving me an opportunity she never had. That memory pushed me through the pain."

 

From theory to practice: Innovating library technology

His unique position within the library has provided an unexpected synergy with his Computer Science studies. "I saw a gap to bridge theory with practical application," Banda explains. "I want to use my tech skills to innovate and make education engaging, developing systems and apps that simplify student life."

He discovered that library science extends far beyond traditional book management. "It's not just borrowing and cataloguing," he says. "There are diverse career paths for a computer scientist, such as systems librarian."

Banda's practical application of his computer science knowledge is evident in his daily work. He plays a key role in managing and configuring the library's technology, including RFID self-check machines and automated chutes. Notably, a YouTube demonstration he created showcases his ability to bridge the digital divide for library users.

The most daunting challenge was his mini-dissertation. "It demanded immense time, often encroaching on my work hours," he recalls. "Balancing coding, documentation, and assisting patrons was incredibly difficult."

 

Evolving technology and support

His fascination with computer science stems from its dynamic nature. "Technology evolves daily," he says. "I'm particularly drawn to artificial intelligence and machine learning, as I envision a future where everything is digitised. My childhood dream was to build robots that could assist in households."

Banda credits several mentors for their profound impact on his academic journey. Prof Richard Ocaya, Prof Lehlohonolo Koao, Dr Andronicus Akinyelu, and Adebola Musa all provided crucial guidance and support. He also acknowledges the invaluable emotional support from Nonhlanhla Moleleki, a counsellor, and Khethiwe Bhiyo, his academic adviser. "The community at large played a vital role," he emphasises.

His advice to students working while studying is simple yet powerful: "Everything is possible with consistency, persistence, determination, and dedication. Keep focused, no matter how long it takes."

His research project, an online dining hall purchasing system, exemplifies his commitment to community-driven innovation. "It has reduced wait times and queues across our campuses," he says proudly.

Looking ahead, Banda plans to pursue a master's degree, aiming to combine his library experience with his technical expertise. "I envision libraries becoming increasingly digitised, and I want to be part of that evolution," he states.

The skills he gained – time management, multitasking, collaboration, and the courage to seek help – will be invaluable in his future endeavours. "Most importantly, believe in yourself," he concluded.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept